Table 3 Clinical characteristics of respective training and test study populations
From: Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease
Training set n = 158 | Age (years) Median (95% CI) | Gender Male: Female | CA19-9 (KU/L) Median (95% CI) | Bilirubin (μmol/L) Median (95% CI) |
|---|---|---|---|---|
PDAC (n = 84) | 66 (64.0-69.0) | 47:37 | 137.5 (62.0-161.4) | 31 (24.5-54.3) |
CP (n = 32) | 53 (48.0-58.6) | 20:12 | 24.5 (11.0-41.0) | 7 (6.0-10.0) |
BBO (n = 13) | 72 (60.7-77.4) | 11:2 | 89 (13.5-228.3) | 69 (11.0-108.6) |
HC (n = 29) | 44 (29.9-54.0) | 14:15 | 4 (2.0-6.0) | NA |
Test Set n = 83 | Age (years) Median (95% CI) | Gender Male: Female | CA19-9 (KU/L) Median (95% CI) | Bilirubin (μmol/L) Median (95% CI) |
PDAC (n = 43) | 68 (64.2-71.8) | 24:19 | 116 (54.9-164.4) | 51 (19.6-114.0) |
CP (n = 17) | 53 (45.1-62.0) | 10:7 | 12 (8.0-24.9) | 6 (5.0-10.0) |
BBO (n = 7) | 64 (38.4-78.5) | 3:4 | 37 (4.5-181.3) | 100 (44.9-374.9) |
HC (n = 16) | 56.5 (36.7-62.1) | 9:7 | 3 (2.6-8.4) | NA |